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Objectives This study sought to evaluate the predictive factors, effects, and safety of balloon post-
dilation (BPD) for the treatment of signiﬁcant paravalvular aortic regurgitation (AR) after transcathe-
ter aortic valve implantation (TAVI).
Background Very few data exist on BPD after TAVI with a balloon-expandable valve.
Methods A total of 211 patients who underwent TAVI with a balloon-expandable valve were in-
cluded. BPD was performed after TAVI if paravalvular AR 2 was identiﬁed by transesophageal
chocardiography. Clinical events and echocardiographic data were prospectively recorded, and
edian follow-up was 12 (6 to 24) months.
esults BPD was performed in 59 patients (28%), leading to a reduction in at least 1 degree of AR
n 71% of patients, with residual AR 2 in 54% of the patients. The predictors of the need for BPD
ere the degree of valve calciﬁcation and transfemoral approach, with valve calciﬁcation volume
2,200 and 3,800 mm3 best determining the need for and a poor response to BPD, respectively.
Patients who underwent BPD had a higher incidence of cerebrovascular events at 30 days (11.9% vs.
2.0%, p  0.006), with most (83%) events within the 24 h after the procedure occurring in patients
who had BPD. No signiﬁcant changes in valve area or AR degree were observed at follow-up in BPD
and no-BPD groups.
Conclusions BPD was needed in about one-fourth of the patients undergoing TAVI with a balloon-
expandable valve and was successful in about one-half of them. A higher degree of valve calciﬁca-
tion and transfemoral approach predicted the need for BPD. BPD was not associated with any dele-
terious effect on valve function at mid-term follow-up, but a higher rate of cerebrovascular events
was observed in patients who had BPD. (J Am Coll Cardiol Intv 2012;5:499–512) © 2012 by the
American College of Cardiology Foundation
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500Transcatheter aortic valve implantation (TAVI) has been
associated with excellent hemodynamic results, but residual
aortic regurgitation (AR), usually secondary to paravalvular
leaks, occurs very frequently (1). Although residual AR after
TAVI is usually trivial or mild, moderate or severe AR
occurs in about 10% of cases (5% to 17%), and this has been
associated with worse acute and mid-term outcomes (2–4).
The presence of a severely calcified native aortic valve might
prevent the complete sealing of the paravalvular space, and
a higher degree of native valve calcification has already been
identified as a predictor of moderate to severe residual AR
after TAVI (5,6).
See page 513
Balloon post-dilation (BPD) has been proposed as an
option to reduce the degree of paravalvular AR by obtaining
a better expansion of the stent containing the transcatheter
valve. In 2 previous studies,
BPD was used in about one-
fourth of the patients after
TAVI with the self-expandable
CoreValve system (Medtronic,
Inc., Minneapolis, Minnesota),
and paravalvular AR was im-
proved in most of the patients
(7,8). However, very few data
exist on the incidence of BPD
after TAVI with a balloon-
expandable valve (9), and no
data are available on the predic-
tors of the need for and the
success of BPD in such cases.
Furthermore, it is unknown
whether by further stretching the
stent prosthesis against the aor-
ic annulus, BPD might be associated with a higher rate of
eriprocedural TAVI complications, such as cerebral embo-
ism or new conduction disturbances leading to the need for
acemaker implantation. Finally, BPD might be associated
ith potential damage to the valve prosthesis leaflets,
eading to more rapid deterioration and structural failure of
he transcatheter valve. The purpose of this study, therefore,
as to evaluate the incidence and predictors of the need for
PD after TAVI with a balloon-expandable valve and the
ffects and potential acute and mid-term complications
ssociated with it.
ethods
Study population and TAVI procedures. A total of 211
patients with severe symptomatic aortic stenosis underwent
TAVI with a balloon-expandable valve (Edwards Sapien or
Abbreviations
and Acronyms
AR  aortic regurgitation
BPD  balloon post-dilation
CI  confidence interval
CT  computed tomography
MLD  minimal lumen
diameter
OR  odds ratio
ROC  receiver-operating
characteristic
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiography
TF  transfemoralSapien XT, Edwards Lifesciences, Inc., Irvine, California) dat our institution. Selection of transfemoral (TF) or
transapical approaches was based on the appropriateness of
the iliofemoral arteries. All procedures were performed
under general anesthesia, and transesophageal echocardiog-
raphy (TEE) was used in all cases. The size of the valve
prosthesis was selected on the basis of aortic annulus
measurements obtained by TEE. A 23-mm valve was
selected if aortic annulus was between 17 and 21 mm, a
26-mm valve if aortic annulus was between 22 and 25 mm,
and a 29-mm valve (only available in the last 6 months of
the study period) if aortic annulus was between 25 and 27
mm. A 20-mm valve was implanted in a single patient with
an aortic annulus of 17.5 mm. Balloon aortic valvuloplasty
was systematically performed before valve implantation.
After valve deployment, a careful evaluation of the presence,
location (paravalvular, transvalvular), and severity of AR was
performed using short- and long-axis TEE views. Semi-
quantitative grading of AR was performed using color
Doppler imaging according to the number of jets, the jet
width in central jets, and the circumferential extent of the
jet(s) in paravalvular AR (10,11). AR was classified as
follows: 0 absent, 1 trace-mild, 2mild-to-moderate,
3  moderate-to-severe, and 4  severe (10). BPD was
ystematically performed in cases of significant paravalvular
R defined as AR 2. The first BPD was performed with
he same balloon of the valve prosthesis and adding 0.5 ml
f saline to the total volume used for valve prosthesis
eployment. After BPD, the presence and degree of AR was
valuated again by TEE. A second BPD was performed at
he discretion of the physician responsible for the procedure
f paravalvular AR 2 persisted after the first BPD. This
econd BPD was performed using the same balloon and
dding an extra 0.5 ml of saline to the total volume used for
he first BPD. The presence, location, and degree of AR
ere re-evaluated by TEE, but no further post-dilation was
erformed irrespective of the result obtained with this
econd BPD. The BPD was considered successful if the
egree of residual AR was reduced by at least 1 degree with
lobal residual AR 2. If significant paravalvular AR
ersisted after BPD and was graded as2, the implantation
f a second valve was considered if valve prosthesis malpo-
itioning (too aortic or ventricular) was suspected as evalu-
ted by TEE. To further evaluate the effects of BPD, the
iameter of the valve prosthesis frame was measured before
nd after each BPD on the mid-esophageal long axis
approximately 120°) of the ascending aorta at 3 different
evels perpendicular to stent axis: ventricular level; valve
evel; and aortic level (Fig. 1). The minimum measurement
btained was considered as the valve prosthesis minimal
umen diameter (MLD). These measurements were per-
ormed offline by 2 cardiologists not involved in the proce-
ure and unaware of the clinical data.
Procedural success and periprocedural complications wereefined on the basis of the Valve Academic Research Consor-
m
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501tium criteria (12). Cerebrovascular events were further classi-
fied as acute (within the 24 h after the procedure or upon
awakeness from general anesthesia) or subacute (between 24 h
and 30 days after TAVI). Baseline, procedural, and hospital-
ization data (including all data on BPD) were prospectively
collected and entered in a dedicated TAVI database. All
procedures were performed under a compassionate clinical use
program approved by Health Canada (Ottawa, Ontario, Can-
ada), and all patients provided written informed consent for the
procedures.
Follow-up. Patients were followed by clinical visits at 1-, 6-,
and 12-month follow-ups, and then yearly. The New York
Heart Association functional class and clinical events, in-
cluding the need for reintervention due to structural failure
of the valve, were recorded and prospectively entered in the
TAVI database. Clinical events were defined on the basis of
the Valve Academic Research Consortium definitions. No
patient was lost at follow-up and median follow-up was 12
(6 to 24) months.
Echocardiography evaluation. Transthoracic echocardiogra-
phy examinations were systematically performed at baseline,
at hospital discharge, at 6 months, and at 1 year. All
examinations were analyzed by experienced technicians
blinded to clinical data and supervised by a cardiologist at
the Echo Core Lab of the Quebec Heart and Lung
Figure 1. MLD of the Valve Prosthesis
Diameter measurements of the valve prosthesis frame (transesophageal echoc
aortic). The smallest measurement was deﬁned as the minimal lumen diameteInstitute. Transvalvular gradients and valve effective orificearea measurements were performed after the methods pre-
viously described by Clavel et al. (13). The severity of AR
was evaluated using the multiparametric approach proposed
in the American Society of Echocardiography/European
Association of Echocardiography guidelines (10,11).
Computed tomography: analysis of valve calciﬁcation. A
total of 134 patients underwent thoracic computed tomog-
raphy (CT) without contrast injection before the procedure.
The CT images of the aortic valve were analyzed offline in
the Cardiac CT Core Lab of the Quebec Heart and Lung
Institute by experienced technicians blinded to clinical data
and supervised by a cardiologist. Three-dimensional multi-
planar reconstruction was performed to examine the aortic
valve in-plane (2-mm slice thickness, 2 to 5 slices per valve
for full coverage) and precisely measure leaflet calcifications
defined as pixels 130 Hounsfield units (TeraRecon, San
Mateo, California). Aortic valve leaflet calcium volumes
(mm3) were determined using the modified Simpson tech-
nique (14).
Statistical analysis. Continuous variables are expressed as
ean  SD or median (interquartile range 25th to 75th
ercentile) depending on variable distribution. Group com-
arisons were analyzed using Student t test or Wilcoxon
rank-sum test for continuous variables, and chi-square-test
or Fisher exact test for categorical variables. The variables
raphy [TEE] images, long-axis view) at 3 different levels (ventricular, mid,
) of the valve prosthesis.ardiogassociated with significant AR (2) and the need for BPD,
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502and those associated with successful (vs. unsuccessful) BPD
were determined by univariate analysis and those variables
with p value 0.05 were entered in a logistic regression
nalysis to determine the independent predictors of the need
or BPD. The univariate normality assumptions were veri-
Table 1. Baseline Characteristics of the Study Popul
All
(N  211)Variables
Baseline variables
Age, yrs 79 8
Male 86 (40.8)
BMI, kg/m2 27 5
Diabetes 77 (36.5)
Dyslipidemia 173 (82.0)
Hypertension 188 (89.1)
Chronic atrial ﬁbrillation/ﬂutter 47 (22.3)
Coronary artery disease 135 (63.9)
Prior CABG 83 (39.3)
Cerebrovascular disease 46 (21.8)
Peripheral vascular disease 79 (37.4)
COPD 62 (29.4)
eGFR 60 ml/min 140 (66.4)
Logistic EuroSCORE, % 24.9 15.2
Porcelain aorta 57 (27.0)
Frailty 38 (18.0)
Echocardiography data
LVEF, % 54 15
Mean aortic gradient, mm Hg 40 16
Aortic valve area, cm2 0.63 0.19
Aortic regurgitation
Grade 1 65 (30.8)
Grade 2 80 (37.9)
Grade 3 18 (8.5)
Grade 4 6 (2.8)
Aortic annulus diameter, mm 21 2.1
Mitral regurgitation 3 53 (25.1)
CT data—valve calciﬁcation
Calcium aortic valve volume, mm3 2,152 (1,343–3,47
Procedural data
Approach
Transfemoral 65 (30.8)
Transapical 146 (69.2)
Prosthesis size
20 mm 1 (0.5)
23 mm 121 (57.6)
26 mm 80 (38.1)
29 mm 8 (3.8)
Ratio diameter prosthesis size/
diameter aortic annulus
1.15 (1.12–1.21)
Values are mean SD, n (%), or median (IQR).
BMI bodymass index; BPD balloon post-dilation; CABG coron
computed tomography; eGFR estimated glomerular filtration rate;interquartile range; LVEF left ventricular ejection fraction.ed with the Shapiro-Wilk tests. Receiver-operating character-
stic (ROC) curve analysis was performed to discriminate
ower of the degree of valve calcification as determined by
T for the need and success of BPD. The maximum sum of
ensitivity and specificity was used as the criterion to
(N  211) According to the Need for BPD
BPD
Yes (n  59) No (n  152) p Value
80 8 79 8 0.891
30 (50.9) 56 (36.8) 0.086
27 6 26 5 0.213
21 (35.6) 56 (36.8) 0.626
53 (89.8) 120 (79.0) 0.065
51 (86.4) 137 (90.1) 0.464
12 (20.3) 35 (23.0) 0.717
37 (62.7) 98 (64.5) 0.873
22 (37.3) 61 (40.1) 0.755
14 (23.7) 32 (21.1) 0.711
22 (37.4) 57 (37.5) 1.00
17 (28.8) 45 (29.6) 1.00
38 (64.4) 102 (67.1) 0.694
23.6 15.3 25.4 15.2 0.501
15 (25.4) 42 (27.6) 0.863
12 (20.3) 26 (17.1) 0.690
56 13 53 15 0.282
45 16 38 16 0.006
0.60 0.15 0.64 0.20 0.140
16 (27.1) 49 (32.2) 0.499
26 (44.1) 54 (35.5)
7 (11.9) 11 (7.2)
1 (1.7) 5 (3.3)
21 2.0 21 2.2 0.212
13 (22.0) 40 (26.3) 0.930
3,369 (2,250–4,665) 1,822 (1,260–2,749) 0.0001
26 (44.1) 39 (25.7) 0.013
33 (55.9) 113 (74.3)
1 (1.7) 0 0.062
28 (48.3) 93 (61.2)
28 (48.3) 52 (34.2)
1 (1.7) 7 (4.6)
1.15 (1.09–1.18) 1.15 (1.13–1.21) 0.211
ry bypass graft; COPD chronic obstructive pulmonary disease; CT
RE European System for Cardiac Operative Risk Evaluation; IQRation
9)
ary arte
EuroSCO
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503identify an optimal cutoff point in the ROC analysis. An
analysis of variance for repeated measures was performed to
test for equal means at different times (baseline; discharge;
and 6, 12, and 24 months) for mean gradient and valve area
values, and a 2-way analysis of variance for repeated mea-
sures with interaction was used to compare the changes at
different time points between groups (BPD vs. no BPD).
Mixed effects ordinal regression was performed to test for
significant changes in AR over time. Cumulative outcomes
at 2-year follow-up were assessed by Kaplan-Meier esti-
mates and compared using the log rank test. The results
were considered significant with p values 0.05. All anal-
yses were conducted using the statistical package SAS
(version 9.2, SAS Institute Inc., Cary, North Carolina).
Results
The clinical, echocardiographic, and procedural character-
istics of the study population are presented in Table 1.
Effects and predictors of BPD. Paravalvular AR occurred in
161 patients (76%) immediately after valve prosthesis im-
plantation as evaluated by TEE and was graded as follows:
grade 1 (48%), grade 2 (11%), grade 3 (15%), and grade 4
(2%). The location of the AR jet was posterior, anterior, and
both anterior and posterior in 71%, 17%, and 18% of the
Figure 2. TEE Images of Paravalvular AR After Valve Implantation
Examples of paravalvular leak location after valve prosthesis implantation as a
and anterior [C]), and in short-axis view (between 9 and 3 o’clock [D]). White
TEE  transesophageal echocardiography.patients, respectively (Fig. 2). In the short-axis view, the AR
jet was localized between 9 and 3 o’clock in 79% of the cases
(Fig. 2). In patients with AR 2, the localization of AR jet
was posterior, anterior, and both anterior and posterior in
65%, 4%, and 31% of the patients, respectively. In the
short-axis view, the AR jet was localized between 9 and 3
o’clock in 84% of the cases. A first BPD was performed in
the 59 patients with paravalvular AR 2 after valve pros-
thesis implantation and was successful (reduction of 1
degree with residual AR 2) in 28 patients (47%). Ten of
the 31 patients with unsuccessful BPD underwent a second
BPD, which was successful in 4 of them. Overall, the grade
of the paravalvular leak was reduced by at least 1 grade in 42
patients (71%), remained the same in 15 patients (26%), and
deteriorated in 2 patients (3%). BPD was considered suc-
cessful in 32 patients (54%), and the degree of paravalvular
AR after BPD was 0 in 9 patients, grade 1 in 23 patients,
grade 2 in 18 patients, grade 3 in 7 patients, and grade 4 in
2 patients (Fig. 3). The circumferential extent of the
paravalvular leak measured in the short-axis view was
reduced from 16  10% to 8  7% (p  0.001), and the
number of paravalvular jets before and after BPD decreased
from 1.4  0.4 to 1.0  0.6 (p  0.053) (Fig. 4). A total of
13 patients (22%) had central AR grade 1 after valve
prosthesis implantation, and the degree of central AR did
d by procedural TEE in long-axis view (posterior [A], anterior [B], posterior
s indicate the location of the paravalvular leak. AR  aortic regurgitation;ssesse
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504not increase in any patient after BPD. After BPD, the stent
MLD increased from 19.4  1.9 mm to 21.1  1.8 mm
p  0.0001) (Fig. 5). The mean absolute increase in stent
LD with BPD was 1.76 mm (95% confidence interval
Figure 3. Paravalvular AR Before and After BPD
Degree of paravalvular aortic regurgitation (AR) before and after balloon
post-dilation (BPD).
Figure 4. Successful BPD
Paravalvular AR as assessed by TEE (long- and short-axis views). (A) TEE images (lo
(B) TEE images (long-axis view) immediately after valve implantation. White arrow
images (short-axis view) immediately after valve implantation. White arrows indic
balloon (adding 0.5 ml of volume to the balloon used for valve prosthesis implan
diately after BPD. White arrows indicate the paravalvular leaks. Note the reduction of
after BPD. White arrows indicate the paravalvular leaks. Note the reduction of the number aCI]: 1.45 to 2.06 mm, p  0.0001), which represented a
ean percent increase of 9.3% (95% CI: 7.6% to 11.1%).
he mean absolute increase in stent MLD was higher in
hose cases with a reduction of at least 1° in paravalvular AR
1.91 mm, 95% CI: 1.59 to 2.24 mm vs. 1.31 mm, 95% CI:
.55 to 2.06; p  0.026) (Fig. 5).
In 5 patients, valve prosthesis malpositioning was sus-
ected and a second valve was implanted after the first
4 patients) or second BPD (1 patient). Paravalvular AR
fter valve-in-valve implantation was significantly reduced
n all patients, and residual paravalvular AR was grade 1 in
patients and grade 2 in 2 patients.
Baseline and procedural characteristics of the patients
rouped according to the need for BPD are shown in
able 1. In the multivariable analysis, the independent
redictors of BPD after TAVI were a larger volume of
alcium (odds ratio [OR] per 500 mm3 increase: 1.26, 95%
I: 1.11 to 1.44, p  0.001) and transfemoral approach
OR: 2.49, 95% CI: 1.03 to 5.97, p  0.042). A calcium
olume cutoff of 2,242 mm3 best predicted the need for
PD with a sensitivity of 78% and specificity of 65% (area under
he ROC curve: 0.74, 95% CI; 0.65 to 0.84, p  0.0001).
Baseline and procedural characteristics of the patients
ho needed BPD, grouped according to the response to
is view) of valve prosthesis implantation. White arrow indicates balloon inﬂation.
cate the paravalvular leaks. The degree of AR was evaluated as 2. (C) TEE
e paravalvular leaks. (D) TEE images (long-axis view) of BPD with a slightly larger
. White arrows indicate balloon inﬂation. (E) TEE images (long-axis view) imme-
mber and extent of paravalvular leaks. (F) TEE images (short-axis view) immediatelyng-ax
s indi
ate th
tation)
the nund extent of paravalvular leaks. Abbreviations as in Figures 1 to 3.
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505BPD (successful vs. unsuccessful) are shown in Table 2. The
degree of valve calcification was the only variable associ-
ated with unsuccessful BPD (p  0.034). Valve calcifi-
cation volume cutoff of 3,874 mm3 best predicted the
occurrence of significant AR (2) that did not respond to
BPD, with a sensitivity of 82% and specificity of 60%
(area under the ROC curve: 0.71, 95% CI: 0.54 to 0.88,
p  0.033).
Clinical outcomes. The 30-day and late outcomes of the
tudy population, grouped according to the need for BPD
fter valve prosthesis implantation, are shown in Table 3.
he need for BPD was associated with a tendency toward a
igher rate of new left bundle branch block, but no
Figure 5. Valve Prosthesis MLD
(A) Valve prosthesis frame MLD before and after BPD. (B) Valve prosthesis
frame minimal diameter before and after BPD, according to the decrease of
at least 1 degree in AR. Abbreviations as in Figures 1 to 3.ifferences in the rate of new pacemaker implantation werebserved between groups. BPD was associated with a higher
ate of cerebrovascular events after the procedure (11.9% vs.
.0%, p  0.006), and these differences were mostly due to
higher incidence of acute (within the first 24 h) cerebro-
ascular events in the BPD group (8.5% vs. 0.7%, p 
.007), with no differences between groups in the rate of
ubacute (24 h) cerebrovascular events (3.4% vs. 1.3%,
 0.312). Baseline and procedural characteristics of the
atients, grouped according to the occurrence of cerebro-
ascular event at 30 days are shown in Table 4. A greater
olume of valve calcification (p  0.028) and BPD (p 
.006) were the 2 variables associated with a higher rate of
erebrovascular events at 30 days.
No differences were observed between groups regarding
ate outcomes (Table 3). The Kaplan-Meier survival curves
or the BPD and no-BPD groups are shown in Figure 6.
he survival curves depending on the occurrence of AR 2
mmediately after the procedure are shown in Figure 7.
Valve hemodynamics. There were no differences between
BPD and no-BPD groups in mean residual gradient and
valve area after TAVI (13  6 mm Hg vs. 12  7 mm Hg,
p  0.156; 1.45  0.28 cm2 vs. 1.45  0.35 cm2, p 
0.943). No significant changes were observed in mean
transvalvular gradient and aortic valve area over time in
the BPD and no-BPD groups (Fig. 8). The degree of
residual AR as evaluated by transthoracic echocardiogra-
phy at hospital discharge and during the follow-up period
in the BPD and no-BPD groups is shown in Figure 8.
The BPD group exhibited a higher rate of residual AR
2 (36% vs. 8%, p  0.001) at hospital discharge. The
degree of residual AR remained stable over time in the 2
groups. No cases of structural failure of the valve occurred
during the follow-up period in any of the groups.
Changes in left ventricular ejection fraction over time are
shown in Figure 9.
Discussion
About one-fourth of the patients undergoing TAVI with a
balloon-expandable valve needed BPD because of paraval-
vular AR 2 immediately after valve prosthesis implanta-
tion. BPD was associated with a reduction of AR by at least
1 degree in 71% of the patients and final AR 2 in 54%. A
higher degree of valve calcification and transfemoral ap-
proach predicted the need for BPD, and the degree of valve
calcification also determined its success, with a valve calcium
volume cutoff of 3,800 mm3 best determining a poor
response to BPD. BPD was associated with a higher rate of
cerebrovascular events, with most strokes in patients who
had BPD occurring immediately after or within the first
24 h after the TAVI procedure. BPD was not associated
with any significant increase in central AR acutely or at
follow-up, and no deterioration in valve hemodynamics
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506(valve area, mean gradient) was observed up to 2-year
follow-up.
Frequency and effectiveness of BPD. Very few data exist on
he use of BPD to reduce the degree of paravalvular AR
fter TAVI. After the implantation of a self-expandable
alve, the rate of BPD has been between 10% and 30%, with
Table 2. Baseline and Procedural Characteristics Ac
Variables
Baseline variables
Age, yrs
Male
BMI, kg/m2
Diabetes
Dyslipidemia
Hypertension
Chronic atrial ﬁbrillation
Coronary artery disease
Prior CABG
Cerebrovascular disease
Peripheral vascular disease
COPD
eGFR 60 ml/min
Logistic EuroSCORE, %
Porcelain aorta
Frailty
Echocardiography data
LVEF, %
Mean aortic gradient, mm Hg
Aortic valve area, cm2
Aortic regurgitation
Grade 1
Grade 2
Grade 3
Grade 4
Aortic annulus diameter, mm
Mitral regurgitation 3
CT data—valve calciﬁcation
Calcium aortic valve volume, mm3
Procedural data
Approach
Transfemoral
Transapical
Prosthesis size
20 mm
23 mm
26 mm
29 mm
Ratio diameter prosthesis size/diameter aortic annulus
Values are mean SD, n (%), or median (IQR).
Abbreviations as in Table 1.reduction in the degree of AR in 60% to 81% of the patients (7,8). However, to date there have been no data on
he usefulness of BPD after TAVI with a balloon-
xpandable valve. The present study shows that BPD was
erformed in up to 28% of the cases after the implantation
f a balloon-expandable Edwards valve due to the occur-
ence of significant paravalvular AR. In accordance with
g to the Success of BPD
Successful BPD
Yes (n  32) No (n  27) p Value
80 9 80 7 0.909
15 (46.8) 15 (55.6) 0.604
28 6 27 5 0.503
14 (43.7) 7 (25.9) 0.181
28 (87.5) 25 (92.6) 0.678
29 (90.6) 22 (81.5) 0.450
8 (25.0) 4 (14.8) 0.518
19 (59.4) 18 (66.7) 0.599
10 (31.3) 12 (44.4) 0.418
8 (25.0) 6 (22.2) 1.00
13 (40.6) 9 (33.3) 0.599
9 (28.1) 8 (29.6) 1.00
20 (62.5) 18 (66.7) 0.790
23.7 17.1 23.5 13.8 0.968
11 (34.4) 4 (14.8) 0.133
6 (18.7) 6 (22.2) 0.757
56 14 56 11 0.952
48 16 41 15 0.072
0.59 0.12 0.62 0.17 0.448
9 (28.1) 7 (25.9) 0.697
16 (50.0) 10 (37.0)
3 (9.4) 4 (14.8)
0 (0) 1 (3.7)
21 2.0 21 2.0 0.957
9 (28.1) 4 (14.8) 0.398
925 (2,099–3,848) 4,081 (3,169–5,281) 0.034
14 (43.8) 12 (44.4) 1.00
18 (56.3) 15 (56.6)
1 (3.1) 0 (0) 0.579
14 (43.7) 14 (53.8)
17 (53.1) 11 (42.3)
0 (0) 1 (3.8)
1.14 (1.09–1.20) 1.15 (1.11–1.18) 0.975cordin
2,revious studies with self-expandable valves, the degree of
i
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507AR was reduced by at least 1 degree in 72% of the cases, but
the BPD was considered successful (final residual AR 2)
n about one-half of the patients. BPD was able to reduce not
nly the extent of the leaks, but also the total number of leaks
n those patients with multiple leaks after TAVI. Interestingly,
akagi et al. (7) used an undersized balloon with respect to the
alve prosthesis size for BPD, whereas a slightly oversized
alloon (0.5 to 1 ml of additional volume) was used in the
resent study. This translated into a significant increase in the
LD of the valve prosthesis as measured by TEE in all
Table 3. 30-Day and Late Clinical Outcomes Accordi
All
(N  211)
30-day outcomes
New left bundle branch block* 55 (40)
New permanent pacemaker 17 (8.0)
Myocardial infarction 2 (1.0)
Highest CK-MB levels, g/l
Transapical approach 22.1 (16.2–33.2)
Transfemoral approach 9.8 (6.9–14.6)
Cerebrovascular event 10 (4.7)
24 h 6 (2.8)
24 h to 30 days 4 (1.9)
TIA 1 (0.5)
Stroke 9 (4.3)
Minor 4 (1.9)
Major 5 (2.4)
Death 20 (9.5)
Late outcomes (30 days)
Months follow-up 12 (6–24)
New permanent pacemaker 8 (3.8)
Myocardial infarction 1 (0.5)
Cerebrovascular event 5 (2.4)
TIA 4 (1.9)
Stroke 1 (0.5)
Minor 0 (0)
Major 1 (0.5)
Death 34 (16.2)
Death or stroke 33 (18.3)
Cumulative outcomes
New permanent pacemaker 25 (11.8)
Myocardial infarction 3 (1.4)
Cerebrovascular event 15 (7.1)
TIA 5 (2.4)
Stroke 10 (4.7)
Minor 4 (1.9)
Major 6 (2.8)
Death 54 (25.7)
Death or stroke 63 (30.0)
Values are n (%) or median (IQR). *Patients at risk 136, after excludin
CK-MB creatine kinase-myocardial band; TIA transient ischemiatients, and a higher degree of lumen diameter increase wasassociated with a lesser grade of residual paravalvular AR.
Importantly, the use of a slightly oversized balloon was not
associated with any increase in central AR and there were no
cases of aortic annulus rupture.
Predictors of BPD. A higher degree of valve calcification and
the use of the TF approach were found to be independent
predictors of significant AR after TAVI, leading to the need
for BPD. The amount of valve calcification has been found
to be a predictor of significant AR after TAVI with
self-expandable and balloon-expandable valves (5,6). In-
BPD
BPD
Yes (n  59) No (n  152) p Value
21 (51) 34 (36) 0.092
5 (8.5) 12 (7.9) 0.890
0 (0) 2 (1.3) 1.00
20.6 (17.4–31.2) 22.6 (16.1–35.8) 0.641
8.4 (6.1–13.2) 10.7 (7.3–17.1) 0.315
7 (11.9) 3 (2.0) 0.006
5 (8.5) 1 (0.7) 0.007
2 (3.4) 2 (1.3) 0.312
1 (1.7) 0 (0) 0.279
6 (10.2) 3 (1.9) 0.016
3 (5.1) 1 (0.7) 0.067
3 (5.1) 2 (1.3) 0.135
6 (10.2) 14 (9.2) 0.799
12 (7–24) 12 (6–23) 0.608
2 (3.4) 6 (3.9) 0.849
0 (0) 1 (0.7) 1.00
1 (1.9) 4 (2.7) 1.00
1 (1.9) 3 (2.0) 1.00
0 (0) 1 (0.7) 1.00
0 (0) 0 (0) —
0 (0) 1 (0.7) 1.00
6 (10.2) 28 (18.5) 0.152
5 (10.9) 28 (20.9) 0.184
7 (11.9) 18 (11.8) 0.996
0 (0) 3 (1.9) 0.561
8 (13.6) 7 (4.6) 0.034
2 (3.4) 3 (1.9) 0.621
6 (10.2) 4 (2.6) 0.031
3 (5.1) 1 (0.7) 0.067
3 (5.1) 3 (2.0) 0.352
12 (20.3) 42 (27.8) 0.296
18 (30.5) 45 (29.8) 1.00
tients with previous left bundle branch block or pacemaker.
; other abbreviations as in Table 1.ng to
g 75 padeed, Schultz et al. (8) showed that a higher degree of aortic
o
p
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508leaflet calcification determined the need for BPD after the
implantation of a self-expandable valve. The present study
shows that the degree of valve calcification is also the most
important factor determining the need for BPD after the
implantation of a balloon-expandable valve. In a step
Table 4. Baseline Characteristics of the Study Popul
Cerebrovascular Events at 30 Days
Variables
Baseline variables
Age, yrs
Male
BMI, kg/m2
Diabetes
Dyslipidemia
Hypertension
Chronic atrial ﬁbrillation/ﬂutter
Coronary artery disease
Prior CABG
Cerebrovascular disease
Peripheral vascular disease
COPD
eGFR 60 ml/min
Logistic EuroSCORE
Porcelain aorta
Frailty
Echocardiography data
LVEF, %
Mean aortic gradient, mm Hg
Aortic valve area, cm2
Aortic regurgitation
Grade 1
Grade 2
Grade 3
Grade 4
Aortic annulus diameter, mm
Mitral regurgitation 3
CT data—valve calciﬁcation
Calcium aortic valve volume, mm3
Procedural data
Approach
Transfemoral
Transapical
Prosthesis size implanted
20 mm
23 mm
26 mm
29 mm
Ratio diameter prosthesis size/diameter aortic annulus
BPD
Values are mean SD, n (%), or median (IQR).
Abbreviations as in Table 1.further, it was also shown that the severity of valve calcifi- tcation was associated not only with the need for but also
with the success of BPD, with a calcium leaflet volume
cutoff of 3,800 mm3 best determining a nonoptimal result
f BPD. A greater amount of valve calcification likely
recludes the complete sealing of the paravalvular space, and
According to the Occurrence of
30-Day Cerebrovascular Event
Yes (n  10) No (n  201) p Value
80 4 79 8 0.865
6 (60.0) 80 (40.0) 0.323
28 6 26 5 0.441
6 (60.0) 71 (35.3) 0.175
9 (90.0) 164 (81.6) 0.694
10 (100) 178 (89.0) 0.606
1 (10.0) 46 (22.9) 0.464
3 (30.0) 132 (65.7) 0.038
3 (30.0) 80 (40.0) 0.743
3 (30.0) 43 (21.4) 0.457
3 (30.0) 76 (37.8) 0.747
3 (30.0) 59 (29.4) 1.00
8 (80.0) 132 (65.7) 0.501
14.7 11.7 25.2 15.2 0.126
5 (50.0) 52 (25.8) 0.138
0 (0) 38 (18.9) 0.214
57 14 54 15 0.528
49 25 40 15 0.091
0.64 0.20 0.63 0.19 0.879
0.465
2 (20.0) 63 (31.3) 0.428
5 (50.0) 75 (37.3)
0 18 (8.9)
1 (10.0) 5 (2.5)
21 2.5 21 2.1 0.409
3 (30.0) 50 (24.8) 0.155
080 (3,884–5,085) 2,121 (1,341–3,369) 0.028
2 (20.0) 63 (31.3) 0.727
8 (80.0) 138 (68.7)
0 1 (0.5) 0.309
6 (60.0) 115 (57.2)
2 (20.0) 78 (38.8)
1 (10.0) 7 (3.5)
1.12 (1.08–1.18) 1.15 (1.12–1.21) 0.089
7 (70.0) 52 (25.9) 0.006ation
4,his seems to be so irrespective of the degree of valve
eter a
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509oversizing. The confirmation of these results in future
studies would add highly clinically relevant information for
the evaluation of potential candidates for TAVI. Interest-
ingly, the use of the TF approach was also a predictor for the
need of BPD after TAVI. In the TF approach, the position
of the valve prosthesis before valve expansion by inflation of
the balloon is nearly systematically very eccentric (usually in
the outer curve of the ascending aorta), whereas in the
transapical approach, the valve can be positioned more
centrally and coaxially with respect to the aortic annulus
(15). One might wonder if the position of the valve
prosthesis before deployment might have an influence
into the uniform and complete covering of the aortic
annulus after valve implantation. Importantly, the TF
approach did not influence the results of BPD after
TAVI.
Safety of BPD. No studies to date had specifically evaluated
Figure 6. Kaplan-Meier Survival Curves at 1-Year Follow-Up Depending on B
(A) Percentage of patients free of stroke. (B) Percentage of patients free of ce
patients free of stroke or death. BPD  balloon post-dilation; TAVI  transcaththe acute and long-term safety of BPD during TAVIprocedures. The present study has shown that BPD was not
associated with a higher rate of myocardial infarction or
pacemaker implantation, though there was a tendency
toward a higher rate of new left bundle branch block in
patients who had BPD. The use of a slightly larger balloon
for BPD might translate into a greater mechanical stress on
the ventricular septum and potential damage to the left
bundle branch system, and future studies will have to further
evaluate the possible relation between BPD and conduction
disturbances. BPD was associated with a higher rate of
cerebrovascular events after TAVI (up to 11.9%), with most
strokes in BPD patients occurring immediately after the
procedure. Transcranial Doppler studies have shown that
cerebral emboli during TAVI procedures mostly occur
during the interaction of the valve prosthesis and the native
calcified aortic valve (i.e., valve positioning and implanta-
tion), but the effect of BPD was not evaluated in these
fter TAVI
ascular events. (C) Percentage of patients free of death. (D) Percentage of
ortic valve implantation.PD A
rebrovstudies (16,17). The dislodgment of calcific particles from
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510the native aortic valve might be favored by BPD, especially
if we consider that the patients who needed BPD exhibited
a higher degree of native valve calcification. In a substudy of
the PARTNER (Placement of Aortic Transcatheter Valve)
trial, Miller et al. (18) showed that a smaller valve area, which
usually correlates with a higher degree of valve calcification
(19,20), was the only predictive factor of stroke early after the
TAVI procedure. However, no information about the rate of
BPD was provided in the PARTNER trial (21). The results of
the present study suggest that there is a relation between BPD
and acute cerebrovascular events after TAVI, but future stud-
ies, including a larger number of patients, will have to deter-
mine whether this association is due to the BPD per se, to the
amount of valve calcification, or both.
The potential effects of BPD on mid- to long-term valve
function were not known. The present study showed that
BPD was not associated with any deleterious effect on valve
hemodynamics as measured by echocardiography up to
1-year follow-up. Indeed, no patient had a significant
increase in central AR during the follow-up period. These
results strongly suggest that BPD has no negative effect on
valve function at mid-term follow-up, and future studies
will have to confirm these results at long-term follow-up.
Study limitations. Although TEE images during the TAVI
rocedures were obtained by experienced operators using a
ystematic view sequence and a standardized approach, we
annot exclude the possible occurrence of inaccurate esti-
ation of the degree of AR after valve prosthesis implan-
ation. In particular, the fact that TEE images were not
alidated in an echo core laboratory, the exclusive use of
emiquantitative color Doppler parameters to evaluate the
egree of AR during the periprocedural period, and to the
Figure 7. Survival Curves at 1-Year Follow-Up, According to Residual AR
Survival curves at 1-year follow-up, depending on the presence of residual
AR 2 after TAVI (as evaluated by TEE at the end of the procedure). Abbre-
viations as in Figures 1, 2, and 6.ery short time allocated for interpretation of the imagesuring the procedure might have led to errors in AR
rading. However, only 12 patients (7.9%) classified as
aving an AR 2 by procedural TEE at the end of the
rocedure had an AR 2 at hospital discharge as evaluated by
ultiparametric approach in the Echo Core Lab (agreement in
he evaluation of AR degree in 92.1% of the patients). Calcium
ata were available only in two-thirds of the patients, and this
ight have led to an underestimation of the importance of this
ariable on the prediction of BPD and clinical events, such as
troke after TAVI. Also, potential underestimation of the
ortic annulus by echocardiography has been suggested by
ome studies using CT angiography for aortic annulus sizing
1), and despite of the absence of differences in prosthesis/
nnulus ratio between BDP and no-BPD groups, we cannot
Figure 8. Valve Hemodynamics During the Follow-Up Period
(A) Mean transvalvular gradients and aortic valve areas over time for BPD
and no-BPD groups. *AVA changes over time between BPD and no BPD
groups; **mean gradient changes over time between BPD and no BPD
groups. (B) Proportion of patients with post-procedural AR in BPD and no-BPD
groups. No change in the frequency and degree of AR was observed during
the follow-up in both groups. *AR changes over time between BPD and no
BPD groups; **AR at discharge between BPD and no BPD groups. Abbrevia-
tions as in Figures 2 and 3.
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511exclude a role for valve undersizing in some patients who
required BPD. The relatively small number of clinical events
after the TAVI procedure precluded performing a multivariate
analysis to test the association between BPD and cerebrovas-
cular events. Future studies, including larger number of pa-
tients and clinical events will have to further evaluate the
association between BPD and stroke.
Conclusions
BPD with a slightly larger balloon was performed in about
one-fourth of the patients after TAVI with a balloon-
expandable valve due to the occurrence of significant para-
valvular leaks. BPD was associated with some decrease in
the extent and/or number of leaks in about two-thirds of the
patients, with one-half of them exhibiting no or trivial or
mild AR at the end of the procedure. The degree of valve
calcification and TF approach were the predictive factors of
Figure 9. Changes in LV Function Over Time After TAVI
(A) Left ventricular (LV) ejection fraction changes over time for BPD and
no-BPD groups. (B) LV ejection fraction changes over time, depending on
the presence of residual AR 2 at hospital discharge. Abbreviations as in
Figures 2, 3, and 6.BPD, and a leaflet calcification volume of3,800 mm3 bestpredicted a poor BPD result. Whereas BPD was not
associated with any deleterious effect on valve function at
mid-term follow-up, a higher incidence of stroke early after
the TAVI procedure was observed in those patients under-
going BPD. The results of this study show the very positive
hemodynamic effects associated with BPD and strongly
suggest that BPD should probably be systematically per-
formed in those patients with significant paravalvular leaks
after valve prosthesis implantation. However, the potential
safety issue of cerebrovascular events associated with BPD
needs to be further evaluated in larger studies in the future.
The use of embolic protection devices might be of particular
importance in such cases to prevent the beneficial effects of
BPD being offset by a higher rate of cerebral embolism.
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